References
- Worms M. The epidemiology of motor neuron disease: A review of recent studies. J Neurol Sci 2001; 191: 3–9
- Jenkinson C, Swash M. Health outcomes measures. In: Brown RH,Menninger V, Swash M. Amyotrophic Lateral Sclerosis, London: Martin Dunitz, 2000: pp. 377-387
- Iwasaki Y, Iguchi H, Ichikawa I, et al. Fatigue and depression areassociated with poor quality of life in ALS. Neurology 2003; 61: 827–828
- Stromberg SF, Weiss DB. Depression and quality of life issues inpatients with amyotrophic lateral sclerosis. Curr Treat Options Neurol 2006; 8: 410–414
- Chió A, Gauthier A, Montuschi A, et al. A cross sectional study ondeterminants of quality of life in ALS. J Neurol Neurosurg Psychiatry 2004; 75: 1597–1601
- Walsh SM, Bremer B, Felgoise FH, et al. Religiousness is related toquality of life in patients with ALS. Neurology 2003; 60: 1527–1529
- Lee JN, Rigby SA, Burcahrdt F, et al. Quality of life issues in motor neuron disease: The development and validation of a coping strategies questionnaire, the MND coping scale. J Neurol Sci 2001; 191: 79–81
- Ware JE, Sherbourne CD. The MOS 36-item short form health survey 1: Conceptual framework and item selection. Med Care 1992; 30: 473–483
- Jenkinson C, Hobart J, Chandola T, et al. Use of the short formhealth survey (SF-36) in patients with amyotrophic lateral sclerosis: Tests of data quality, score reliability response rate and scaling assumptions. J Neurol 2002; 249: 178–183
- Mc Guire D, Garrison L, Armon C, et al. Relationship of the tufts quantitative neuromuscular exam and sickness impact profile in measuring disease progression in ALS. Neurology 1996; 46: 1442–1444
- O'Boyle CA. The schedule for the evaluation of individual quality of life (SEIQoL). Int J Ment Health 1994; 23: 3–23
- Cohen SR, Mount BM, Strobel MG, et al. The McGill Quality of Life Questionnaire: A measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 1995; 9: 2007–2019
- Jenkinson C, Fitzpatrick R, Brennan C, et al. Development and validation of the ALSAQ-40. J Neurol 1999; 246 (Suppl. 3): S16—S21
- Jenkinson C, Fitzpatrick R. Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: Development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiat 2001; 70: 70–73
- Jenkinson C, Fitzpatrick R, Michael Swash, et al. ALSAQ User Manual: Amyotrophic Lateral Sclerosis Assessment Questionnaire, Oxford: Health Services Research Unit, 2001
- Jenkinson C, Fitzpatrick R, Swash M, et al. Comparison of the 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) with a short-form five-item version (ALSAQ-5) in a longitudinal survey. Clin Rehabil 2007; 21 (3): 266–272
- Yamaguchi T, Ohbu S, Saito M, et al. Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis-assessment questionnaire 40 (ALSAQ-40). No To Shinkei 2004; 6: 483–694
- Maessen M, Post MW, Maillé R, et al. Validity of the Dutch version of the Amyotrophic Lateral Sclerosis Assessment Questionnaire, ALSAQ-40, ALSAQ-5. Amyotroph Lateral Scler 2007; 8: 96–100
- Brooks BR, Miller RG, Swash M, et al. El Escorial Revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 292–299
- Jenkinson C, Fitzpatrick R, Brennan C, et al. Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord 1999; 1: 33–40
- Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (Phase III). J Neurol Sci 1999; 169: 13–21
- Apolone G, Mosconi P, Ware JE. Questionario Sullo Stato di Salute SF-36, Milano: Guerini e Associati, 1997
- R Development Core Team. R: A Language and Environment for Statistical Computing, Vienna: R Foundation for Statistical Computing, 2005, available at: http://www.R-projectorg
- Brown RH, Menninger V, Swash M. Amyotrophic Lateral Sclerosis, London: Martin Dunitz, 2001
- Jenkinson C, Hobart J, Chandola T, et al. Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: Tests of data quality, score reliability response rate and scaling assumptions. J Neurol 2002; 249: 178–183
- Simmons Z, Felgoise FH, Bremer BA, et al. The ALSSQOL balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology 2006; 67: 1659–1664
- Damiano A, Patrick DL, Guzman GI, et al. Measurement of health related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies. Med Care 1999; 37: 15–26
- Kiebert GM, Green C, Murphy C, et al. Patient's health related quality of life and utilies associated with different sates of amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 87–93
- Sancho PO, Boisson D. Handicap and quality of life evaluation in ALS. Rev Neurol (Paris) 2006; 162: 4S205-4S207
- Neudert C, Wasner M, Borasio GD. Patients' assessment of quality of life instruments: A randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 103–109
- Clarke S, Hickey A, O'Boyle C, et al. Assessing individual quality of life in amyotrophic lateral sclerosis. Qual Life Res 2001; 10: 149–158
- McDonald ER, Wiedenfeld SA, Hillel A, et al. Survival in amyotrophic lateral sclerosis: The role of psychological factors. Arch Neurol 1994; 51: 17–23